TY - JOUR
T1 - Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib
AU - Joensuu, Heikki
AU - Eriksson, Mikael
AU - Hall, Kirsten Sundby
AU - Hartmann, Jörg T.
AU - Pink, Daniel
AU - Schütte, Jochen
AU - Ramadori, Giuliano
AU - Hohenberger, Peter
AU - Duyster, Justus
AU - Al-Batran, Salah Eddin
AU - Schlemmer, Marcus
AU - Bauer, Sebastian
AU - Wardelmann, Eva
AU - Sarlomo-Rikala, Maarit
AU - Nilsson, Bengt
AU - Sihto, Harri
AU - Ballman, Karla V.
AU - Leinonen, Mika
AU - Dematteo, Ronald P.
AU - Reichardt, Peter
PY - 2014/8/1
Y1 - 2014/8/1
N2 - BACKGROUND Little is known about the factors that predict for gastrointestinal stromal tumor (GIST) recurrence in patients treated with adjuvant imatinib. METHODS Risk factors for GIST recurrence were identified, and 2 risk stratification scores were developed using the database of the Scandinavian Sarcoma Group (SSG) XVIII trial, where 358 patients with high-risk GIST with no overt metastases were randomly assigned to adjuvant imatinib 400 mg/day either for 12 or 36 months after surgery. The findings were validated in the imatinib arm of the American College of Surgeons Oncology Group Z9001 trial, where 359 patients with GIST were randomized to receive imatinib and 354 were to receive placebo for 12 months. RESULTS Five factors (high tumor mitotic count, nongastric location, large size, rupture, and adjuvant imatinib for 12 months) were independently associated with unfavorable recurrence-free survival (RFS) in a multivariable analysis in the SSGXVIII cohort. A risk score based on these 5 factors had a concordance index with GIST recurrence of 78.9%. When a simpler score consisting of the 2 strongest predictive factors (mitotic count and tumor site) was devised, the groups with the lowest, intermediate high, and the highest risk had 5-year RFS of 76.7%, 47.5%, and 8.4%, respectively. Both scores were strongly associated with RFS in the validation cohort (P < .001 for each comparison). CONCLUSIONS The scores generated were effective in stratifying the risk of GIST recurrence in patient populations treated with adjuvant imatinib. Patients with nongastric GIST with a high mitotic count are at a particularly high risk for recurrence.
AB - BACKGROUND Little is known about the factors that predict for gastrointestinal stromal tumor (GIST) recurrence in patients treated with adjuvant imatinib. METHODS Risk factors for GIST recurrence were identified, and 2 risk stratification scores were developed using the database of the Scandinavian Sarcoma Group (SSG) XVIII trial, where 358 patients with high-risk GIST with no overt metastases were randomly assigned to adjuvant imatinib 400 mg/day either for 12 or 36 months after surgery. The findings were validated in the imatinib arm of the American College of Surgeons Oncology Group Z9001 trial, where 359 patients with GIST were randomized to receive imatinib and 354 were to receive placebo for 12 months. RESULTS Five factors (high tumor mitotic count, nongastric location, large size, rupture, and adjuvant imatinib for 12 months) were independently associated with unfavorable recurrence-free survival (RFS) in a multivariable analysis in the SSGXVIII cohort. A risk score based on these 5 factors had a concordance index with GIST recurrence of 78.9%. When a simpler score consisting of the 2 strongest predictive factors (mitotic count and tumor site) was devised, the groups with the lowest, intermediate high, and the highest risk had 5-year RFS of 76.7%, 47.5%, and 8.4%, respectively. Both scores were strongly associated with RFS in the validation cohort (P < .001 for each comparison). CONCLUSIONS The scores generated were effective in stratifying the risk of GIST recurrence in patient populations treated with adjuvant imatinib. Patients with nongastric GIST with a high mitotic count are at a particularly high risk for recurrence.
KW - adjuvant therapy
KW - gastrointestinal stromal tumor
KW - imatinib
KW - predictive score
UR - http://www.scopus.com/inward/record.url?scp=84904759514&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84904759514&partnerID=8YFLogxK
U2 - 10.1002/cncr.28669
DO - 10.1002/cncr.28669
M3 - Article
C2 - 24737415
AN - SCOPUS:84904759514
SN - 0008-543X
VL - 120
SP - 2325
EP - 2333
JO - Cancer
JF - Cancer
IS - 15
ER -